Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC11A2 | P49281 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4013917 | 0.84 | SLC11A2 (0.52) | SLC11A2AHRALOX5 | |
| SCHEMBL14068647 | 0.80 | SLC11A2 (0.37) | SLC11A2AHRALOX5 | |
| SCHEMBL4160541 | 0.74 | SLC11A2 (0.76) | SLC11A2 | |
| Bromide SCHEMBL4162322 | 0.73 | SLC11A2 (0.74) | SLC11A2 | |
| SCHEMBL4019634 | 0.73 | GLA (0.48) | SLC11A2 | |
| SCHEMBL7962346 | 0.72 | ALOX5 (0.54) | SLC11A2AHRALOX5 | |
| SCHEMBL9694899 | 0.72 | GPR84 (0.34) | — | |
| SCHEMBL4015859 | 0.70 | — | — | |
| SCHEMBL9328769 | 0.68 | CYP1A2 (0.63) | — | |
| SCHEMBL4163251 | 0.67 | MCL1 (0.41) | AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | TFRC, SLC40A1, FECH | SLC11A2 77/4885AHR 990/4885ALOX5 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.